Evidence-based guideline for risk stratification, empiric therapy, prophylaxis, and management of febrile neutropenia in cancer patients.
A comprehensive, evidence-based clinical guideline for the prevention, risk stratification, and management of febrile neutropenia (FN) in adult oncology patients. This resource synthesizes recommendations from major international professional societies and expert panels to provide a single integrated reference for oncologists, infectious disease specialists, emergency medicine physicians, hospitalists, and advanced practice providers who manage cancer patients at risk for or presenting with neutropenic fever.1 2 3 4 5 6
Febrile neutropenia remains one of the most common and potentially life-threatening complications of cytotoxic chemotherapy, with reported mortality rates of 5% in solid tumors and up to 11% in hematologic malignancies. Timely recognition, appropriate risk stratification, and rapid initiation of empiric broad-spectrum antibiotics are the cornerstones of management and have been shown to significantly reduce morbidity and mortality.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Definition, Risk Stratification & Initial Evaluation | Definitions and diagnostic criteria; MASCC risk index; CISNE score; high-risk vs. low-risk classification; initial workup including history, physical examination, laboratory studies, blood cultures, and imaging |
| Part 2 | Empiric Antibiotic Therapy & Outpatient Management | Inpatient empiric monotherapy and combination regimens with dosing; indications for vancomycin and other anti-gram-positive agents; duration of therapy and de-escalation criteria; outpatient eligibility, oral antibiotic regimens, and monitoring |
| Part 3 | Antimicrobial Prophylaxis, G-CSF, & Special Situations | Fluoroquinolone prophylaxis; antifungal prophylaxis; antiviral and PJP prophylaxis; G-CSF primary and secondary prophylaxis with dosing; therapeutic G-CSF in established FN; persistent fever; documented infections |
| Part 4 | Antifungal Therapy, Central Line Infections & Infection Prevention | Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia; central line-associated bloodstream infections in neutropenic patients; infection prevention measures; patient and caregiver education |
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology (ASCO) and Infectious Diseases Society of America (IDSA) clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-1453. ↩︎
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2011;52(4):e56-e93. ↩︎
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. ↩︎
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer (MASCC) risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051. ↩︎
National Comprehensive Cancer Network (NCCN). Prevention and treatment of cancer-related infections. NCCN Clinical Practice Guidelines in Oncology. Version 1.2024. ↩︎
Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465-471. ↩︎
Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.
Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.
Empiric intravenous antibiotic monotherapy and combination regimens with complete dosing, indications for vancomycin and anti-gram-positive agents, antibiotic de-escalation and duration criteria, outpatient eligibility for low-risk febrile neutropenia, oral antibiotic regimens, and monitoring requirements.
Definitions of febrile neutropenia, MASCC risk index, CISNE score, high-risk versus low-risk classification, and comprehensive initial workup including history, physical examination, laboratory studies, blood cultures, and imaging.